A dual GLP-1 and glucagon receptor agonist with potent fat-burning and liver-protective effects.
Simultaneously activates GLP-1 receptors (reducing appetite and slowing gastric emptying) and glucagon receptors (increasing hepatic fat oxidation and thermogenesis). The glucagon component meaningfully increases energy expenditure, differentiating it from pure GLP-1 agonists.
Developed by Boehringer Ingelheim (BI 456906). In Phase 2 NASH trials, survodutide showed significant liver fat reduction and NASH resolution. Phase 3 trials for obesity and NASH are ongoing.
The glucagon receptor component adds meaningful energy expenditure and hepatic fat clearance on top of appetite suppression, potentially addressing a broader metabolic phenotype than GLP-1 monotherapy.